Is Interpace Biosciences, Inc. (IDXG) a Buy, Sell, or Hold?
OTC : IDXG
Interpace Biosciences, Inc. — News
$1.7 USD
$0.09 (5.59%)
- Volume
- 13.7K
- Average Volume
- 5.5K
- Market Capitalization
- $47.09M
- P/E Ratio
- 0.32
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.40
- Year Low
- $0.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.22
| Source | Headline |
|---|---|
|
Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST)
Profitability This table compares Ethema Health and Interpace Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ethema Health -11.61% N/A -7.48% Interpace Biosciences 65.25% 219.07% 105.05% Insider and Institutional Ownership 5.7% of Interpace Biosciences shares are held by institutional investors. 55.7% of Ethema Health shares defenseworld.net - 2026-08-11 03:59:17 |
|
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Q2 Revenue of $9. 1 millionQ2 Income from Continuing Operations of $0. 3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36. 1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug. globenewswire.com - 2026-08-10 16:35:00 |
|
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update. globenewswire.com - 2026-05-12 16:06:19 |
|
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update. globenewswire.com - 2026-05-12 16:06:00 |
